{"originalText": "，患者于4月余前入院，诊为结肠癌，于2015-08-11在全麻上行腹腔镜上左半结肠姑息性切除术，，术中见：腹腔内有淡黄色腹水约200ML，肿瘤位于升结肠中段，明显侵出浆膜面，形成不完全梗阻，近端肠管明显增厚扩张，周围可见数个肿大淋巴结，盆腔内可见多个绿豆大小的种植转移病灶，遂行下术，术顺。术后病理示(左半结肠)，：结肠溃疡型管状腺癌II级，侵出外膜层，侵犯神经组织，手术标本双切端及另送(近切端)、(远切端)均未见癌浸润。找到回肠周淋巴结0/5个、结肠周淋巴结5/22个，及另送(回结肠动脉根部）淋巴结0/3个，见癌转移。阑尾组织。，免疫组化：CK18（+++），CGA（-），CD56（-），SY（-），KI67（60%）。该病例未检测到KRAS基因12、13号密码子热点突变。该病例未检测到BRAF基因V600E突变，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。2015.08.28、2015.09.23、2015.10.21、2015.11.12、2015.12.06行“奥沙利铂200MGIVGGTD1+希罗达1500MGPOBIDD1-14”方案化疗，辅以保胃、保肝、止吐、增强免疫、营养补液等治疗。过程顺利，未见明显化疗副反应。此次为化疗再次入院。门诊拟以“升结肠癌伴腹腔种植（PT4BN2AM1IV期)术后化疗”收入院，患者出院后饮食、夜休可，无腹痛、腹胀、发热，体重无明显改变。", "entities": [{"label_type": "疾病和诊断", "overlap": 0, "start_pos": 13, "end_pos": 16}, {"label_type": "手术", "overlap": 0, "start_pos": 33, "end_pos": 47}, {"end_pos": 55, "label_type": "解剖部位", "overlap": 0, "start_pos": 53}, {"end_pos": 61, "label_type": "解剖部位", "overlap": 0, "start_pos": 60}, {"end_pos": 78, "label_type": "解剖部位", "overlap": 0, "start_pos": 73}, {"end_pos": 99, "label_type": "解剖部位", "overlap": 0, "start_pos": 95}, {"end_pos": 121, "label_type": "解剖部位", "overlap": 0, "start_pos": 118}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 150, "end_pos": 170}, {"end_pos": 220, "label_type": "解剖部位", "overlap": 0, "start_pos": 214}, {"end_pos": 231, "label_type": "解剖部位", "overlap": 0, "start_pos": 225}, {"end_pos": 252, "label_type": "解剖部位", "overlap": 0, "start_pos": 240}, {"end_pos": 264, "label_type": "解剖部位", "overlap": 0, "start_pos": 262}, {"end_pos": 451, "label_type": "药物", "overlap": 0, "start_pos": 447}, {"end_pos": 467, "label_type": "药物", "overlap": 0, "start_pos": 464}, {"end_pos": 493, "label_type": "解剖部位", "overlap": 0, "start_pos": 492}, {"end_pos": 496, "label_type": "解剖部位", "overlap": 0, "start_pos": 495}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 543, "end_pos": 568}, {"end_pos": 589, "label_type": "解剖部位", "overlap": 0, "start_pos": 588}, {"end_pos": 592, "label_type": "解剖部位", "overlap": 0, "start_pos": 591}]}
